{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:30:29Z","timestamp":1783409429554,"version":"3.54.6"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2015A030313808"],"award-info":[{"award-number":["2015A030313808"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Program of Guangzhou City","award":["20171A011267"],"award-info":[{"award-number":["20171A011267"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jchromb.2018.05.026","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T12:45:40Z","timestamp":1526647540000},"page":"506-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study"],"prefix":"10.1016","volume":"1092","author":[{"given":"Xiao-Jia","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-Zhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Wei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Guan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2018.05.026_bb0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jchromb.2018.05.026_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02244958","article-title":"Fluoxetine: a review of receptor and functional effects and their clinical implications","volume":"107","author":"Beasley","year":"1992","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jchromb.2018.05.026_bb0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jad.2012.11.001","article-title":"Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis","volume":"146","author":"Silva","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0020","first-page":"e1","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jchromb.2018.05.026_bb0025","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0731-7085(95)01651-1","article-title":"Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection","volume":"14","author":"Chiu","year":"1996","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0030","first-page":"1327","article-title":"Reversed phase high-performance liquid chromatography for determination of plasma olanzapine and pharmacokinetics of olanzapine in healthy Chinese volunteers","volume":"26","author":"Zhu","year":"2006","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.jchromb.2018.05.026_bb0035","first-page":"281","article-title":"Analysis of olanzapine in human plasma with reversed-phase high performance liquid chromatography","volume":"19","author":"Xiao","year":"2001","journal-title":"Se Pu"},{"key":"10.1016\/j.jchromb.2018.05.026_bb0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jchromb.2014.12.023","article-title":"An UPLC-MS\/MS method for the analysis of glimepiride and fluoxetine in human plasma","volume":"980","author":"Qiu","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0045","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jssc.200700153","article-title":"Fluoxetine and norfluoxetine analysis by direct injection of human plasma in a column switching liquid chromatographic system","volume":"31","author":"Santos-Neto","year":"2008","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.aca.2008.03.036","article-title":"Determination of fluoxetine in plasma by gas chromatography-mass spectrometry using stir bar sorptive extraction","volume":"614","author":"Fernandes","year":"2008","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jchromb.2018.05.026_bb0055","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/bmc.1597","article-title":"Simultaneous determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by LC-MS\/MS using supported liquid extraction","volume":"25","author":"Li","year":"2011","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jchromb.2015.10.029","article-title":"A UPLC\u2013MSMS method for the analysis of olanzapine in serum\u2014with particular emphasis on drug stability testing","volume":"1006","author":"Andreassen","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0065","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/bmc.1750","article-title":"Development of a rapid and sensitive SPE-LC-MS\/MS method for the simultaneous estimation of fluoxetine and olanzapine in human plasma","volume":"26","author":"Gopinath","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0070","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1080\/10826076.2012.723098","article-title":"Simultaneous determination of olanzapine and fluoxetine in human plasma by LC-MS\/MS and its application to pharmacokinetic study","volume":"36","author":"Ravinder","year":"2013","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0075","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpba.2013.10.033","article-title":"Simultaneous determination of olanzapine and fluoxetine in human plasma by LC-MS\/MS: its pharmacokinetic application","volume":"90","author":"Bonde","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0080","doi-asserted-by":"crossref","first-page":"34342","DOI":"10.1039\/C5RA02489G","article-title":"A simple and automated online SPE-LC-MS MS method for simultaneous determination of olanzapine, fluoxetine and norfluoxetine in human plasma and its application in therapeutic drug monitoring","volume":"5","author":"Fan","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0085","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00216-008-2498-6","article-title":"Comparison of extraction efficiencies and LC-MS-MS matrix effects using LLE and SPE methods for 19 antipsychotics in human blood","volume":"393","author":"Saar","year":"2009","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0090","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0095","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.4155\/bio.14.252","article-title":"European Bioanalysis Forum: recommendation on dealing with hemolyzed and hyperlipidemic matrices","volume":"6","author":"Ingelse","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2018.05.026_bb0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jchromb.2017.08.018","article-title":"Insulin glargine and its two active metabolites: a sensitive (16pM) and robust simultaneous hybrid assay coupling immunoaffinity purification with LC-MS\/MS to support biosimilar clinical studies","volume":"1063","author":"Xu","year":"2017","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2018.05.026_bb0105","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.jchromb.2011.05.027","article-title":"Analyte and internal standard cross signal contributions and their impact on quantitation in LC-MS based bioanalysis","volume":"879","author":"Tan","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023218300370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023218300370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T19:39:15Z","timestamp":1565293155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023218300370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":21,"alternative-id":["S1570023218300370"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2018.05.026","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous analysis of olanzapine, fluoxetine, and norfluoxetine in human plasma using liquid chromatography-mass spectrometry and its application to a pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2018.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}